{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=73", "query": { "intervention": "Placebo once daily", "page": 73 }, "page_size": 10 }, "pagination": { "page": 73, "page_size": 10, "total_count": 5512, "total_pages": 552, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=74&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=72&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T12:03:59.687Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01059864", "title": "Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Atorvastatin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2010-02", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-12-13", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059864" }, { "nct_id": "NCT05103332", "title": "Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Indapamide", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Olmesartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Zilebesiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 663, "start_date": "2021-11-05", "completion_date": "2024-09-13", "has_results": true, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 74, "location_summary": "Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103332" }, { "nct_id": "NCT00303498", "title": "A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diastolic Heart Failure" ], "interventions": [ { "name": "Sitexsentin sodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2006-03-27", "completion_date": "2008-05-01", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303498" }, { "nct_id": "NCT02778399", "title": "A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "OBE2109", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ObsEva SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 328, "start_date": "2016-07", "completion_date": "2019-07-01", "has_results": true, "last_update_posted_date": "2022-07-21", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 71, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02778399" }, { "nct_id": "NCT01738698", "title": "Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 40mg", "type": "DRUG" }, { "name": "SPD489 100mg", "type": "DRUG" }, { "name": "SPD489 160mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2012-11-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 1, "location_summary": "Irving, Texas", "locations": [ { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01738698" }, { "nct_id": "NCT03152409", "title": "Salicylic Augmentation in Depression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression", "Depressive Disorder", "Major Depressive Disorder", "Treatment Resistant Depression" ], "interventions": [ { "name": "Aspirin 325mg", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jessica Harder", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2018-11-15", "completion_date": "2021-02-16", "has_results": true, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152409" }, { "nct_id": "NCT04556032", "title": "Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "L-Ergothioneine 10 mg/d", "type": "DIETARY_SUPPLEMENT" }, { "name": "L-Ergothioneine 25 mg/d", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Midwest Center for Metabolic and Cardiovascular Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "55 Years to 79 Years" }, "enrollment_count": 4, "start_date": "2020-09-09", "completion_date": "2020-10-30", "has_results": false, "last_update_posted_date": "2020-11-04", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04556032" }, { "nct_id": "NCT00625443", "title": "Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Thrombocytopenic Purpura" ], "interventions": [ { "name": "Blinded (placebo)", "type": "DRUG" }, { "name": "Open Label (Avatrombopag tablets)", "type": "DRUG" }, { "name": "Blinded (Avatrombopoag tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2007-05", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2018-03-16", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 12, "location_summary": "Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Manchester", "state": "Connecticut" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00625443" }, { "nct_id": "NCT01313676", "title": "Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "fluticasone furoate/vilanterol", "type": "DRUG" }, { "name": "fluticasone furoate", "type": "DRUG" }, { "name": "vilanterol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 16568, "start_date": "2011-01-25", "completion_date": "2015-07-15", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 506, "location_summary": "Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313676" }, { "nct_id": "NCT05358717", "title": "A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Huntington Disease" ], "interventions": [ { "name": "PTC518", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 159, "start_date": "2022-06-03", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-04T12:03:59.687Z", "location_count": 4, "location_summary": "La Jolla, California • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05358717" } ] }